Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Decrease in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 792,811 shares, a decline of 22.3% from the December 31st total of 1,019,881 shares. Based on an average daily trading volume, of 265,433 shares, the days-to-cover ratio is currently 3.0 days. Currently, 3.1% of the company’s shares are short sold. Currently, 3.1% of the company’s shares are short sold. Based on an average daily trading volume, of 265,433 shares, the days-to-cover ratio is currently 3.0 days.

Senti Biosciences Stock Performance

Shares of NASDAQ SNTI traded down $0.01 during midday trading on Tuesday, hitting $1.00. 244,490 shares of the stock traded hands, compared to its average volume of 276,280. The firm has a market capitalization of $26.29 million, a P/E ratio of -0.30 and a beta of 2.13. Senti Biosciences has a one year low of $0.95 and a one year high of $5.10. The firm has a 50-day moving average of $1.34 and a two-hundred day moving average of $1.58.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). Equities analysts forecast that Senti Biosciences will post -14.54 earnings per share for the current fiscal year.

Institutional Trading of Senti Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC bought a new position in shares of Senti Biosciences during the 3rd quarter valued at about $117,000. Geode Capital Management LLC grew its holdings in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after buying an additional 117,588 shares in the last quarter. Finally, Armistice Capital LLC bought a new stake in Senti Biosciences in the 2nd quarter worth approximately $1,883,000. 25.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on SNTI. Leerink Partners started coverage on shares of Senti Biosciences in a research note on Friday, November 21st. They set an “outperform” rating and a $6.00 target price for the company. Wall Street Zen raised Senti Biosciences to a “sell” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, January 22nd. HC Wainwright started coverage on shares of Senti Biosciences in a research note on Tuesday, October 14th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Chardan Capital lifted their target price on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.00.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.